Tag: narrow therapeutic index
International Perspectives on NTI Generics: Regulatory Approaches Compared
NTI generics require strict regulatory oversight due to their narrow safety margin. This article compares how the FDA, EMA, Health Canada, and others regulate these high-risk drugs, highlighting differences in bioequivalence standards, approval timelines, and substitution rules.
Dec 19 2025
